Jennifer Schwartz1, Umer I Chaudhry, Andrew Suzo1, Nicholas Durkin, Allison M Wehr1, Kathy S Foreman1, Kristen Tychonievich, Dean J Mikami1, Bradley J Needleman1, Sabrena F Noria2. 1. The Comprehensive Weight Management and Bariatric Surgery Program, Center for Minimally Invasive Surgery, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, Room 558, Columbus, OH, 43210, USA. 2. The Comprehensive Weight Management and Bariatric Surgery Program, Center for Minimally Invasive Surgery, The Ohio State University Wexner Medical Center, 410 W. 10th Ave, Room 558, Columbus, OH, 43210, USA. Sabrena.noria@osumc.edu.
Abstract
BACKGROUND: Bariatric surgery is an effective therapeutic option for management of obesity. However, weight recidivism (WR) and weight loss plateau (WLP) are common problems. We present our experience with the use of two pharmacotherapies in conjunction with our standard diet and exercise program in those patients who experienced WR or WLP. METHODS: From June 2010 to April 2014, bariatric surgery patients who experienced WR or WLP after undergoing Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB), and who were treated with phentermine (Ph) or phentermine-topiramate (PhT), were reviewed retrospectively. Generalized estimating equations were used to compare patient weights through 90 days between initial surgery type and medication type. Patient weights, medication side effect, and co-morbidities were collected during the first 90 days of therapy. RESULTS: Fifty-two patients received Ph while 13 patients received PhT. Overall, patients in both groups lost weight. Among those whose weights were recorded at 90 days, patients on Ph lost 6.35 kg (12.8% excess weight loss (EWL); 95% confidence interval (CI) 4.25, 8.44) and those prescribed PhT lost 3.81 kg (12.9% EWL; CI 1.08, 6.54). Adjusting for baseline weight, time since surgery, and visit through 90 days, patients treated with Ph weighed significantly less than those on PhT throughout the course of this study (1.35 kg lighter; 95% CI 0.17, 2.53; p = 0.025). There were no serious side effects reported. CONCLUSIONS: Phentermine and phentermine-topirimate in addition to diet and exercise appear to be viable options for weight loss in post-RYGB and LAGB patients who experience WR or WLP.
BACKGROUND: Bariatric surgery is an effective therapeutic option for management of obesity. However, weight recidivism (WR) and weight loss plateau (WLP) are common problems. We present our experience with the use of two pharmacotherapies in conjunction with our standard diet and exercise program in those patients who experienced WR or WLP. METHODS: From June 2010 to April 2014, bariatric surgery patients who experienced WR or WLP after undergoing Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB), and who were treated with phentermine (Ph) or phentermine-topiramate (PhT), were reviewed retrospectively. Generalized estimating equations were used to compare patient weights through 90 days between initial surgery type and medication type. Patient weights, medication side effect, and co-morbidities were collected during the first 90 days of therapy. RESULTS: Fifty-two patients received Ph while 13 patients received PhT. Overall, patients in both groups lost weight. Among those whose weights were recorded at 90 days, patients on Ph lost 6.35 kg (12.8% excess weight loss (EWL); 95% confidence interval (CI) 4.25, 8.44) and those prescribed PhT lost 3.81 kg (12.9% EWL; CI 1.08, 6.54). Adjusting for baseline weight, time since surgery, and visit through 90 days, patients treated with Ph weighed significantly less than those on PhT throughout the course of this study (1.35 kg lighter; 95% CI 0.17, 2.53; p = 0.025). There were no serious side effects reported. CONCLUSIONS:Phentermine and phentermine-topirimate in addition to diet and exercise appear to be viable options for weight loss in post-RYGB and LAGB patients who experience WR or WLP.
Entities:
Keywords:
Bariatric surgery; Phentermine; Phentermine–topiramate; Weight loss plateau; Weight recidivism
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; C David Sjöström; Kristjan Karason; Hans Wedel; Sofie Ahlin; Åsa Anveden; Calle Bengtsson; Gerd Bergmark; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Kristina Narbro; Ingmar Näslund; Torsten Olbers; Per-Arne Svensson; Lena M S Carlsson Journal: JAMA Date: 2012-01-04 Impact factor: 56.272
Authors: Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: Daniéla Oliveira Magro; Bruno Geloneze; Regis Delfini; Bruna Contini Pareja; Francisco Callejas; José Carlos Pareja Journal: Obes Surg Date: 2008-04-08 Impact factor: 4.129
Authors: Daniel McKenna; Don Selzer; Michael Burchett; Jennifer Choi; Samer G Mattar Journal: Surg Obes Relat Dis Date: 2013-12-18 Impact factor: 4.734
Authors: W Timothy Garvey; Donna H Ryan; Michelle Look; Kishore M Gadde; David B Allison; Craig A Peterson; Michael Schwiers; Wesley W Day; Charles H Bowden Journal: Am J Clin Nutr Date: 2011-12-07 Impact factor: 7.045
Authors: Maria Paula Carlin Cambi; Giorgio Alfredo Pedroso Baretta; Daniéla De Oliveira Magro; Cesar Luiz Boguszewski; Igor Braga Ribeiro; Pichamol Jirapinyo; Diogo Turiani Hourneaux de Moura Journal: Obes Surg Date: 2021-01-03 Impact factor: 4.129
Authors: Nawfal W Istfan; Wendy A Anderson; Donald T Hess; Liqun Yu; Brian Carmine; Caroline M Apovian Journal: Obesity (Silver Spring) Date: 2020-06 Impact factor: 5.002
Authors: Nawfal W Istfan; Marine Lipartia; Wendy A Anderson; Donald T Hess; Caroline M Apovian Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958